A carregar...
Projeto de investigação
Coimbra Chemistry Center
Financiador
Autores
Publicações
Spiro-Lactams as Novel Antimicrobial Agents
Publication . Alves, Américo; G. Alves, Nuno; Caratão, Cátia; Esteves, Margarida; Fontinha, Diana; Bártolo, Inês; Soares, Maria I. L.; Lopes, Susana M. M.; Prudêncio, Miguel; Taveira, Nuno; Melo, Teresa M. V. D. Pinho E
Introduction: Structural modulation of previously identified lead spiro-β-lactams with antimicrobial activity was carried out.
Objective: The main objective of this work was to synthesize and evaluate the biological activity of novel spiro-lactams based on previously identified lead compounds with antimicrobial activity.
Methods: The target chiral spiro-γ-lactams were synthesized through 1,3-dipolar cycloaddition reaction of a diazo-γ-lactam with electron-deficient dipolarophiles. In vitro activity against HIV and Plasmodium of a wide range of spiro-β-lactams and spiro-γ-lactams was evaluated. Among these compounds, one derivative with good anti-HIV activity and two with promising antiplasmodial activity (IC50 < 3.5 µM) were identified.
Results: A novel synthetic route to chiral spiro-γ-lactams has been established. The studied β- and γ- lactams were not cytotoxic, and three compounds with promising antimicrobial activity were identified, whose structural modulation may lead to new and more potent drugs.
Conclusion: The designed structural modulation of biologically active spiro-β-lactams involved the replacement of the four-membered β-lactam ring by a five-membered γ-lactam ring. Although conformational and superimposition computational studies revealed no significant differences between β- and γ- lactam pharmacophoric features, the studied structural modulation did not lead to compounds with a similar biological profile. The observed results suggest that the β-lactamic core is a requirement for the activity against both HIV and Plasmodium.
Unidades organizacionais
Descrição
Palavras-chave
Contribuidores
Financiadores
Entidade financiadora
Fundação para a Ciência e a Tecnologia
Programa de financiamento
6817 - DCRRNI ID
Número da atribuição
UID/QUI/00313/2019
